In yesterday’s Wall Street session, Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares traded at $1.09, up 0.93% from the previous session.
DNA stock price is now -17.14% away from the 50-day moving average and -34.04% away from the 200-day moving average. The market capitalization of the company currently stands at $2.22B.
With the price target reduced from $3.50 to $2.50, Raymond James Downgraded its rating from Outperform to Mkt Perform for Ginkgo Bioworks Holdings Inc (NYSE: DNA). , while ‘Goldman’ rates the stock as ‘Sell’
In other news, Dmytruk Mark E., insider sold 38,826 shares of the company’s stock on Mar 04 ’24. The stock was sold for $48,765 at an average price of $1.26. Upon completion of the transaction, the insider now directly owns 808,125 shares in the company, valued at $0.88 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 02 ’24, Dmytruk Mark E. sold 39,569 shares of the business’s stock. A total of $47,799 was realized by selling the stock at an average price of $1.21. This leaves the insider owning 761,737 shares of the company worth $0.83 million. A total of 33.94% of the company’s stock is owned by insiders.
During the past 12 months, Ginkgo Bioworks Holdings Inc has had a low of $1.05 and a high of $2.55. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 6.11, and a quick ratio of 6.11. The fifty day moving average price for DNA is $1.3060 and a two-hundred day moving average price translates $1.6500 for the stock.
The latest earnings results from Ginkgo Bioworks Holdings Inc (NYSE: DNA) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.11, missing analysts’ expectations of -$0.1 by -0.01. This compares to -$0.06 EPS in the same period last year. The net profit margin was -355.08% and return on equity was -63.02% for DNA. The company reported revenue of $34.76 million for the quarter, compared to $98.28 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -64.64 percent. For the current quarter, analysts expect DNA to generate $46.43M in revenue.
